Please verify that you are a Healthcare Professional. Register for complete access to all the content!
New international urticaria guideline advances bio...
A major international update to urticaria care is providing clinicians with more detailed recommendations on disease classification, diagnostic w...
Six-year safety evaluation of upadacitinib in mode...
Atopic dermatitis (AD) is marked by eczematous lesions, severe pruritus, and skin dryness that can hamper quality of life.
2 min
Six-year safety evaluation of upadacitinib in moderate-to-severe...
Upadacitinib demonstrates a stable long-term safety profile in moderate-to-severe atopic dermatitis over six years, with no new or unexpected saf...
New international urticaria guideline advances biomarker-guided d...
Updated international urticaria guidelines recommend precision-based diagnosis, biomarker-guided evaluation, and stepwise escalation to targeted...
Rapid assessment of chronic spontaneous urticaria activity using...
First-day urticaria activity score (UAS1) accurately reflects weekly disease activity and quality-of-life impairment in chronic spontaneous urtic...
Breastfeeding for ≥4 months linked to lower asthma risk through e...
Exclusive breastfeeding for a minimum of four months is linked to lower asthma risk and reduced allergic responsiveness from childhood through yo...
Real-world survey exposes treatment challenges in allergic rhinit...
Allergic rhinitis management shows substantial gaps, including low healthcare engagement, poor treatment adherence, and limited use of advanced a...
Canadian experts update guidance on allergic rhinitis diagnosis a...
New Canadian AR guidance supports flexible diagnostic testing, individualized first-line therapy selection, and broader use of SLIT and SCIT whil...
Intranasal antihistamines and corticosteroids for AR: Insights fr...
Fixed intranasal antihistamine–corticosteroid combinations demonstrate superior quality-of-life and health utility outcomes in allergic rhi...
Remibrutinib in CSU: Findings from Phase 3 BISCUIT study
Remibrutinib (25 mg twice daily) rapidly improves itch and hives in chronic spontaneous urticaria and sustains symptom control over 52 weeks with...
Cetirizine among top performers for nasal symptoms in allergic rh...
Cetirizine, ebastine, and rupatadine perform better for nasal symptoms, while loratadine and desloratadine show relatively better effects on ocul...
Topical therapies for atopic dermatitis: A review of safety, effi...
Emerging nonsteroidal topical therapies offer safer and more effective alternatives for atopic dermatitis management.
Long-term dupilumab shows psychological benefits in atopic dermat...
Dupilumab improves psychological well-being at 52 weeks in moderate-to-severe atopic dermatitis, while showing sustained reductions in disease se...
Bee allergy linked to higher H. pylori infection and gastric infl...
Bee allergy significantly correlates with higher H. pylori infection rates and increased gastric inflammation.